I'm LongbridgeAI, I can summarize articles.Revenue: As of FY2026 Q3, the actual value is USD 1.494 M.
EPS: As of FY2026 Q3, the actual value is USD -0.34.
EBIT: As of FY2026 Q3, the actual value is USD -11.85 M.
Revenue
Citius Pharmaceuticals, Inc. reported revenues of $1,493,788 for the three months ended June 30, 2026, compared to no revenue in the same period of 2025. For the nine months ended June 30, 2026, revenues were $7,105,197, also with no revenue in the prior year period. This revenue was primarily generated from commercial sales of LYMPHIR®.
Gross Profit
Gross profit for the three months ended June 30, 2026, was $1,001,945, representing a gross margin of approximately 67%. For the nine months ended June 30, 2026, gross profit was $5,495,268, with a gross margin of approximately 77%.
Operating Expenses
Research and Development (R&D) expenses decreased to $1,053,869 for the three months ended June 30, 2026, from $1,621,325 in the comparable 2025 period. For the nine months ended June 30, 2026, R&D expenses were $4,287,106, down from $7,514,888 in the prior year period. Amortization of In-Process Research and Development expense was $1,720,312 for the three months and $4,014,062 for the nine months ended June 30, 2026. General and Administrative (G&A) expenses increased to $6,149,173 for the three months ended June 30, 2026, from $4,447,008 in the prior year. For the nine months ended June 30, 2026, G&A expenses totaled $38,261,001, up from $14,626,882 in the nine months ended June 30, 2025, primarily due to a non-recurring $19.7 million contract cancellation charge and increased expenses related to the commercial launch of LYMPHIR®. Stock-based compensation expense was $3,810,665 for the three months ended June 30, 2026, compared to $2,719,674 in 2025. For the nine months, it was $11,879,167, up from $7,946,529 in the prior year period. Total operating expenses were $12,734,019 for the three months ended June 30, 2026, and $58,441,336 for the nine months ended June 30, 2026.
Operating Loss
Citius Pharmaceuticals, Inc. reported an operating loss of - $11,732,074 for the three months ended June 30, 2026, and - $52,946,068 for the nine months ended June 30, 2026.
Net Loss
Net loss applicable to common stockholders was - $8,862,843 for the three months ended June 30, 2026, compared to - $8,789,872 for the same period in 2025. For the nine months ended June 30, 2026, the net loss was - $38,314,768, compared to - $29,474,623 for the nine months ended June 30, 2025.
Cash and Cash Equivalents
As of June 30, 2026, cash and cash equivalents totaled $17,007,523, an increase from $4,252,290 as of September 30, 2025.
Cash Flows from Operating Activities
Net cash used in operating activities for the nine months ended June 30, 2026, was - $22,986,413, compared to - $14,671,948 for the same period in 2025.
Cash Flows from Investing Activities
Net cash used in investing activities for the nine months ended June 30, 2026, was - $7,000,000, primarily due to license fee payments.
Cash Flows from Financing Activities
Net cash provided by financing activities for the nine months ended June 30, 2026, was $42,741,646. This included approximately $4.5 million in net proceeds from a registered direct offering, $9.7 million in net proceeds from warrant exercises, and $10.0 million funded under a Citius Oncology senior secured term loan facility.
Operational Metrics and Business Highlights
LYMPHIR® is now available in 44 institutions, with new ordering institutions increasing by 80% and institutional vial orders from wholesalers growing by 31%. July 2026 recorded 383 vials ordered, marking the largest vial order month to date, and the company has secured near universal payer coverage. Citius Oncology expanded its commercial organization with 21 field-based professionals and 8 medical science liaisons, with nationwide deployment completed in August 2026. Phase 1 investigator-initiated data for LYMPHIR® in combination with pembrolizumab showed a 24% overall response rate and a 48% clinical benefit rate in gynecologic malignancies. Additionally, Phase 1 data for LYMPHIR® administered prior to CAR-T therapy in DLBCL demonstrated an 86% objective response rate, including 57% complete response, with no dose-limiting toxicities.
Outlook
Citius Pharmaceuticals, Inc. anticipates increased engagement with priority treatment centers, support for formulary adoption, and broader access for eligible patients as the LYMPHIR® launch matures. Management believes LYMPHIR® has potential beyond cutaneous T-cell lymphoma, as indicated by positive signals from ongoing Phase 1 trials. The company remains focused on disciplined execution to build the long-term sustainable value of LYMPHIR®.